DarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for Multiple Conditions
DarioHealth Corp. (Nasdaq: DRIO) announced a study published in the Journal of Medical Internet Research highlighting the effectiveness of its integrated digital therapeutics platform in managing both diabetes and hypertension. The study revealed that users managing both conditions saw a significant reduction in average blood glucose and blood pressure levels, with 27% achieving more than a 10mmHg systolic blood pressure reduction. Dario emphasizes the importance of a holistic approach to chronic condition management and aims to lead in integrated health solutions.
- Published a study demonstrating effective management of diabetes and hypertension using a single digital platform.
- Significant average blood glucose reduction observed in users managing both conditions.
- 27% of users achieved over 10mmHg reduction in systolic blood pressure.
- None.
NEW YORK, Feb. 9, 2022 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced the publication of a retrospective, real-world study demonstrating the impact of managing blood pressure and diabetes together on the same digital platform in the leading peer-reviewed journal for digital medicine and health, the Journal of Medical Internet Research.
To better understand the impact of an integrated, multi-condition digital therapeutics platform, the study compared the results of two propensity-matched groups of people using Dario's digital therapeutic platform to monitor and manage blood sugar levels. Six months of monitoring blood sugar levels with Dario were included in the test group before and after adding blood pressure measurements, while the control group used Dario to manage blood sugar only.
The study showed a significant improvement in average blood glucose levels during the first six months of using Dario to manage both blood glucose and blood pressure, while the control group average blood glucose levels did not change, demonstrating the positive impact of managing both conditions using a single digital application.
In addition, analysis of the monthly average blood pressure during the first six months of monitoring showed a significant decrease in systolic and diastolic pressures during this period, in that
Diabetes and hypertension are commonly co-occurring chronic conditions. People living with Type 2 diabetes are commonly found to have elevated blood pressures, and evidence suggests that poor management of either condition can exacerbate outcomes bi-directionally, leading to overall poor health and significantly increased healthcare costs. Dario's single platform for the management of multiple chronic conditions aims to improve overall health by recognizing the need for holistic, person-centered care rather than single condition care to improve overall outcomes.
"I am thrilled to share learnings from our holistic approach to chronic condition management. This research offers solid evidence that approaching the management of multiple chronic conditions, with a single digital app, can be more effective than a single condition approach," said Yifat Hershcovitz, PhD., Scientific and Clinical Director at DarioHealth and supervisor of the study.
The research was published with co-authors David A. Horwitz, M.D., DLH Biomedical Consulting, and Marilyn D. Ritholz, MD, PhD., Senior Psychologist Behavioral Health, Joslin Diabetes Center.
"We know many chronic conditions commonly co-occur and often share underlying contributing behaviors, which is why Dario designs solutions focused on the user's overall health needs and not siloed conditions. Health plans, employers and providers are seeking integrated solutions with evidence of multi-condition efficacy. Dario is proud to be leading in this area and we believe that the present study is just the beginning as we expand and explore the power of our holistic platform," said Omar Manejwala, Chief Medical Officer at DarioHealth.
To access the study, click here.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.
Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.
Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.
The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.
On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
About JMIR Publications
JMIR Publications (www.jmirpublications.com) is a leading, born-digital open-access publisher of academic journals and other innovative scientific communication products that focus on medicine, health and technology. Its flagship journal, the Journal of Medical Internet Research, is the leading digital health journal globally in terms of quality/visibility in the medical informatics category and is the largest journal in the field. The journal focuses on emerging technologies, medical devices, apps, engineering, telehealth, and informatics applications for patient education, disease prevention, population health and clinical care, and is read by clinicians, allied health professionals, informal caregivers, and patients. Visit www.jmir.org
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the improvements of conditions patients experienced while using its digital therapeutic platform, the belief that health plans, employers and providers are seeking integrated solutions with evidence of multi-condition efficacy and its belief that the present study is just the beginning as its expand and explore the power of its wholistic platform. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contact
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220
Media Contact:
Josephine Galatioto
Josephine.Galatioto@russopartnersllc.com
+1-212-845-4262
View original content:https://www.prnewswire.com/news-releases/dariohealth-publishes-clinical-outcomes-demonstrating-the-impact-of-using-a-single-digital-therapeutics-platform-for-multiple-conditions-301478603.html
SOURCE DarioHealth Corp.
FAQ
What are the key findings of the DarioHealth study published on Feb 9, 2022?
How does DarioHealth's platform improve chronic condition management?
What percentage of users saw a significant reduction in blood pressure while using DRIO's platform?
Where was the DarioHealth study published?
What is the stock symbol for DarioHealth Corp.?
